Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma
Open Access
- 5 September 2013
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 28 (2) , 398-403
Abstract
Multiple myeloma (MM) consists of several distinct cytogenetic subtypes, and we hypothesized that each subtype may have a unique mode of initial presentation and end-organ damage. We studied 484 patients with newly diagnosed MM to determine the relationship between specific myeloma-defining event (MDE) and the cytogenetic subtype. Patients were divided into four non-overlapping groups based on the MDE at diagnosis: isolated renal failure, isolated anemia, isolated lytic bone disease or a combination (mixed). MM with translocations without trisomies accounted for 30% of all patients, but accounted for 50% of patients with renal failure. Specifically, the t(14;16) translocation accounted for only 5% of all MM patients, but was present in 13.5% of patients with renal failure as MDE. Among patients with t(14;16), 25% presented with renal failure only as MDE. Patients with isolated renal failure as MDE had significantly poorer survival compared with all other groups, whereas patients with bone disease as MDE had the best outcome (P<0.001). Our findings support the hypothesis that in addition to prognostic differences, there is significant heterogeneity in clinical presentation associated with the cytogenetic subtype, suggesting that MM encompasses a group of cytogenetically and phenotypically distinct disorders rather than a single entity.Keywords
This publication has 23 references indexed in Scilit:
- Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myelomaLeukemia, 2013
- Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative projectLeukemia, 2012
- Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogeneticsBlood, 2012
- Multiple myeloma: 2012 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2011
- Treatment of multiple myelomaNature Reviews Clinical Oncology, 2011
- Evidence for Cytogenetic and Fluorescence In Situ Hybridization Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel TherapiesMayo Clinic Proceedings, 2010
- Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus GuidelinesMayo Clinic Proceedings, 2009
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight reviewLeukemia, 2009
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myelomaLeukemia, 2008
- Review of 1027 Patients With Newly Diagnosed Multiple MyelomaMayo Clinic Proceedings, 2003